Personalized Medicine and Other Emerging Therapy in Hematologic Malignancies
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".
Deadline for manuscript submissions: closed (15 May 2024) | Viewed by 1202
Special Issue Editor
Special Issue Information
Dear Colleagues,
Hematologic malignancies are cancers that originate in hematopoietic tissues (such as bone marrow) or cells of the immune system. There are three main types of hematological malignancies: leukemia, lymphoma, and multiple myeloma. There are increasing reports that hematological malignancies, such as leukemia and lymphoma, afflict millions of adults and children every year, and are often deadly. Therefore, it is increasingly urgent to explore emerging therapy methods to treat hematologic malignancies.
This Special Issue will focus a broad range of innovative treatments, including bispecific antibodies, new monoclonal antibodies, CAR-T cells, small molecules in targeted cancer therapy, immunoconjugates, targeted drugs, immunotherapy, tyrosine kinase inhibitors, amongst others.
This Special Issue aims to provide a discussion platform for the diagnosis and treatment of hematological malignancies in personalized medicine and to promote academic exchanges and experience sharing of personalized medicine in hematological malignancies. In this Special Issue, we aim to focus on personalized medicine for hematologic malignancies; original research articles, review articles, etc., are welcome.
Dr. Khalil Saleh
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hematologic malignancies
- CAR-T cells
- targeted cancer therapy
- personalized medicine
- immunotherapy
- bispecific antibodies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
